Form 4: Denali Therapeutics Director Sells Shares to Cover Tax Obligations

Denali Therapeutics director Steve E. Krognes sold 3,339 shares of common stock at $20.81 per share to cover tax obligations related to vested restricted stock units.

Summary

• Steve E. Krognes, a director at Denali Therapeutics, sold 3,339 shares of common stock on January 7, 2025, at a price of $20.81 per share.
• The sale was executed to satisfy tax obligations arising from the settlement of previously vested restricted stock units.
• Following the transaction, Mr. Krognes directly owns 25,757 shares of common stock, which includes 5,967 unvested RSUs.
• He also indirectly owns 781,797 shares held in The Steve Edward Krognes Revocable Trust, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction by a company director and does not indicate any positive or negative sentiment towards the company's performance or future prospects.

Industry Context

This is a routine transaction for a company director to manage their personal tax obligations related to equity compensation. It is common for executives to sell shares to cover taxes when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by company directors to cover tax obligations are a common practice across the biotechnology industry.
• Similar transactions are regularly reported by directors at companies like Biogen, Amgen, and Regeneron, as part of their equity compensation management.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale by a director to cover tax obligations.

Key Dates

Keywords

Denali Therapeutics, insider trading, Form 4, stock sale, restricted stock units, tax obligations, director, equity